期刊： PHARMACOGENOMICS, 2023; 24 (17)
Aim: To advance clinical adoption and implementation of pharmacogenomics (PGx) testing, barriers and facilitators to these efforts must be understood.......
期刊： PHARMACOGENOMICS, 2023; 24 (16)
Aim: Identify oncology healthcare providers' attitudes toward barriers to and use cases for pharmacogenomic (PGx) testing and implications for prescri......
期刊： PHARMACOGENOMICS, 2023; 24 (10)
Aim: To understand how attitudes toward pharmacogenomic (PGx) testing among healthcare providers varies by specialty. Methods: Providers reported comf......
期刊： PHARMACOGENOMICS, 2023; 24 (2)
Aim: This retrospective, case-control study evaluated the effect of pharmacogenomic testing (PGT) on the management of pediatrics with anxiety, major ......
期刊： PHARMACOGENOMICS, 2023; 24 (6)
Plain language summaryAs a new-generation aromatic antiepileptic drug, oxcarbazepine (OXC) is often used for epilepsy treatment. It is known that when......
期刊： PHARMACOGENOMICS, 2023; 24 (8)
Plain language summaryAcute lymphoblastic leukemia (ALL) is the most common malignancy affecting children in Zimbabwe and 6-mercaptopurine is frequent......
期刊： PHARMACOGENOMICS, 2023; 24 (8)
Aim: Examining the association between HLA-A/B alleles and different carbamazepine (CBZ)-induced cutaneous adverse reactions in the Chinese population......
期刊： PHARMACOGENOMICS, 2023; ()
Sequencing exomes of synchronous and metachronous liver metastases of colorectal cancer has potential to enhance treatment, since they can have molecu......
期刊： PHARMACOGENOMICS, 2023; 24 (14)
Purpose: This work was designed to identify the pharmacogenetic profile of Brazilian psychiatric patients receiving psychoactive drug treatment accord......
期刊： PHARMACOGENOMICS, 2023; 24 (15)
Aim: Tuberous sclerosis complex (TSC) is a rare disease that produces multisystemic disorders. Everolimus (EVR) is the only immunosuppressive drug app......
期刊： PHARMACOGENOMICS, 2023; 24 (2)
Breast cancer was declared the most prevalent type of cancer in 2020. Among other factors, treatment response can be affected by genetic polymorphisms......
期刊： PHARMACOGENOMICS, 2023; 24 (1)
Anxiety and depression coexist with cognitive impairment in Alzheimer's disease along with other concomitant disorders (>60%), which require multip......
期刊： PHARMACOGENOMICS, 2023; 24 (6)
Aim: To evaluate the association between OPRK1 rs963549 and rs997917 and opioid use disorder (OUD) and related phenotypes.Methods: A sample of 208 ind......
期刊： PHARMACOGENOMICS, 2023; 24 (7)
Background: Pain is a common cause of hospitalization in sickle cell disease (SCD) patients. Failure to effectively control pain remains a challenge i......
期刊： PHARMACOGENOMICS, 2023; 24 (1)
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of invasive non-Hodgkin lymphoma. There is great heterogeneity in its molecular biolo......
